search
Back to results

Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia

Primary Purpose

Androgenetic Alopecia

Status
Recruiting
Phase
Phase 2
Locations
Indonesia
Study Type
Interventional
Intervention
Finasteride
Minoxidil
Sponsored by
Indonesia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Androgenetic Alopecia focused on measuring Finasteride topical, Minoxidil topical, Male androgenetic alopecia

Eligibility Criteria

18 Years - 59 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria: Male aged from 18-59 years diagnosed with androgenic alopecia Androgenic alopecia type III-V according to Hamilton-Norwood criteria Willing to participate in this research by signing the consent form after receiving an explanation from the researcher Willing to not cutting the hair nor coloring the hair during the study Exclusion Criteria: Diagnosed with other infectious or inflammatory skin disease in the scalp Using oral medications or vitamins that aim to increase the amount of hair in the last 1 month Using topical medication that aim to increase the amount of hair in the last 2 weeks Undergoing cosmetic procedure for AGA therapy such as low-level laser therapy (LLLT) procedures, platelet-rich plasma (PRP) injections, or microneedling within the last 3 months Have sexual disorder such as decreased libido Have a history of allergy or irritant contact dermatitis to the minoxidil and finasteride

Sites / Locations

  • University IndonesiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Combination of minoxidil 5% topical and finasteride 0,1% topical group

Minoxidil 5% topical group

Arm Description

Combination of minoxidil 5% solutio and finasteride 0,1% solutio which has administered topically

Minoxidil 5% solutio which has administered topically

Outcomes

Primary Outcome Measures

Hair density
Density of the hair is the number of hair strands per square inch of the scalp measured by trichoscan
Hair diameter (mean thickness)
Hair diameter is the midline of the hair shaft measured by trichoscan
Side effects
Incidence of side effects

Secondary Outcome Measures

Velus hair percentage ( hair rate vellus)
Vellus hair is a hair that is less than 30 micrometer in diameter, lacks a medulla hair, and is 2 cm in length measured by trichoscan
Terminal hair percentage (hair rate terminal)
Terminal hair is a hair that has a hair more than 60 micrometer, contains the medulla and can be up to 100 cm in length measured by trichoscan
Dermoscopy
Dermoscopy is a non-invasive technique that allows more detailed examination of the scalp and hair shaft under magnification

Full Information

First Posted
August 4, 2023
Last Updated
September 21, 2023
Sponsor
Indonesia University
search

1. Study Identification

Unique Protocol Identification Number
NCT05990400
Brief Title
Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia
Official Title
Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2023 (Actual)
Primary Completion Date
October 30, 2023 (Anticipated)
Study Completion Date
December 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indonesia University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
A double-blind, randomized, controlled trial of 40 male patients with androgenetic alopecia was conducted. All subject were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical
Detailed Description
All subject were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical The primary outcome was increase of the hair density and hair diameter (mean thickness) measured by trichoscan Measurements were done at baseline and every four weeks for twelve weeks. Additionally, side effects of therapy was also measured.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Androgenetic Alopecia
Keywords
Finasteride topical, Minoxidil topical, Male androgenetic alopecia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Eligible subjects were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical. The allocation sequence was generated with a computer by an analyst.
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Triple (Participant, Investigator, Outcomes Assessor) The allocation sequence was generated with a computer by an analyst. The allocation sequence was concealed from the investigators, outcomes assessor, and subjects.
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Combination of minoxidil 5% topical and finasteride 0,1% topical group
Arm Type
Experimental
Arm Description
Combination of minoxidil 5% solutio and finasteride 0,1% solutio which has administered topically
Arm Title
Minoxidil 5% topical group
Arm Type
Active Comparator
Arm Description
Minoxidil 5% solutio which has administered topically
Intervention Type
Drug
Intervention Name(s)
Finasteride
Intervention Description
finasteride topical 0,1%
Intervention Type
Drug
Intervention Name(s)
Minoxidil
Intervention Description
minoxidil topical 5%
Primary Outcome Measure Information:
Title
Hair density
Description
Density of the hair is the number of hair strands per square inch of the scalp measured by trichoscan
Time Frame
4 times of measurement in 3 months
Title
Hair diameter (mean thickness)
Description
Hair diameter is the midline of the hair shaft measured by trichoscan
Time Frame
4 times of measurement in 3 months
Title
Side effects
Description
Incidence of side effects
Time Frame
4 times of measurement in 3 months
Secondary Outcome Measure Information:
Title
Velus hair percentage ( hair rate vellus)
Description
Vellus hair is a hair that is less than 30 micrometer in diameter, lacks a medulla hair, and is 2 cm in length measured by trichoscan
Time Frame
4 times of measurement in 3 months
Title
Terminal hair percentage (hair rate terminal)
Description
Terminal hair is a hair that has a hair more than 60 micrometer, contains the medulla and can be up to 100 cm in length measured by trichoscan
Time Frame
4 times of measurement in 3 months
Title
Dermoscopy
Description
Dermoscopy is a non-invasive technique that allows more detailed examination of the scalp and hair shaft under magnification
Time Frame
4 times of measurement in 3 months

10. Eligibility

Sex
Male
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
59 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male aged from 18-59 years diagnosed with androgenic alopecia Androgenic alopecia type III-V according to Hamilton-Norwood criteria Willing to participate in this research by signing the consent form after receiving an explanation from the researcher Willing to not cutting the hair nor coloring the hair during the study Exclusion Criteria: Diagnosed with other infectious or inflammatory skin disease in the scalp Using oral medications or vitamins that aim to increase the amount of hair in the last 1 month Using topical medication that aim to increase the amount of hair in the last 2 weeks Undergoing cosmetic procedure for AGA therapy such as low-level laser therapy (LLLT) procedures, platelet-rich plasma (PRP) injections, or microneedling within the last 3 months Have sexual disorder such as decreased libido Have a history of allergy or irritant contact dermatitis to the minoxidil and finasteride
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Farah F Lubis, MD
Phone
081385088998
Email
farahfaulinlubis@gmail.com
Facility Information:
Facility Name
University Indonesia
City
Jakarta
State/Province
Other (Non U.s.)
ZIP/Postal Code
10250
Country
Indonesia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Farah F Lubis, MD
Phone
081385088998
Email
farahfaulinlubis@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia

We'll reach out to this number within 24 hrs